Authors
Latest:
New dawn of GA management requires renewed attention to imagingIt is important that the ophthalmic community redouble our efforts in following patients with age-related macular degeneration (AMD) using optical coherence tomography (OCT) to find the early signs of geographic atrophy (GA).
Latest:
Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trials in nAMDDr Marco Zarbin presents his talk from the 2023 ASRS annual meeting, where he explores the impact of disease activity criteria on drug durability estimations in clinical trials and includes a comparative analysis across multiple clinical trials in neovascular AMD (age-related macular degeneration).
Latest:
Ultra-widefield imaging can enhance efficiency for practicesPhysicians can discover, diagnose, document, treat diseases that might go undetected
Latest:
Noninfectious uveitis: Meeting the challengeChronic cases can be difficult for retina specialists; treatment is satisfying.
Latest:
Achieving high-definition slit lamp imaging via smartphone mirroringThis affordable device allows the view through a slit lamp to be shared in real time or recorded, for teaching and reference purposes.
Latest:
Satellite clinics and other strategies to enhance rural ophthalmologyProactive communication and leveraging advanced, yet reliable, technologies to maximize efficiency are essential pillars of success.
Latest:
The future of retina careRetina is a rapidly advancing field with promising research, technology, and treatment areas. Two stand out as particularly exciting.
Latest:
Using virtual reality mobility testing as a standardized clinical end point in inherited retinal disordersThe use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.
Latest:
Investigating the quality of real-world evidence in retinal diseaseReal-world evidence is growing in importance as a source of information that can help support clinical decision-making when evaluated properly.
Latest:
ASRS 2025: PER-001 improved structure and visual function in patients with diabetic retinopathyJustis Ehlers, MD, FASRS, presented "PER-001, a Long-acting Endothelin Antagonist Intravitreal Implant, Improved Structure and Visual Function in Patients With Diabetic Retinopathy," during the 2025 ASRS meeting held in Long Beach, California.
Latest:
Using virtual reality mobility testing as a standardized clinical end point in inherited retinal disordersThe use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.
Latest:
Improving vitrectomy outcomes and patient care in academic and private settingsReliable visualization tools, especially those indicated for ocular use, are crucial for success.
Latest:
Precision medicine in diabetic macular edema: Expert consensus on the efficacy and safety of the 0.19-mg fluocinolone acetonide implantResults from expert surveys provide snapshots of our understanding of DME and shed light on where the 0.19-mg FAc implant stands in the current standard of care.
Latest:
Dexamethasone rebuttal: Who should perform intravitreal injections?In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.
Latest:
Multiple intravitreal injections and their effect on the optic nerve head in patients with CRVOResearch from the iMIND lab at Duke University.
Latest:
Avirmax Biopharma prepares for IND-enabling study of ABI-201ABI-201 aims to prevent dry AMD and other retinal disorders in patients.
Latest:
Kapil Mishra discusses radiation retinopathy in uveal melanomaKapil Mishra, MD, discusses an overview of radiation retinopathy and its challenges in treating uveal melanoma from his presentation "Radiation Retinopathy: Future Strategies,"
Latest:
Sustained drug delivery in ophthalmologyCurrent options, challenges in developing novel therapies.
Latest:
Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic AtrophyA retina specialist shares his presentation from the 2023 ASRS Annual Meeting, which describes a study comparing the efficacy of 2 FDA-approved treatments for geographic atrophy based on an anchored matching-adjusted indirect comparison of phase 3 trial findings.
Latest:
Improving patient experience with intravitreal injectionsThe role of anesthetics in streamlining efficiency and elevating patient care.
Latest:
ARVO 2025: Carl Danzig, MD, recaps the first stage of a phase 3 study of drop-based DME therapyAccording to Dr. Danzig, the DIAMOND trial demonstrates efficacy of OCS-01, a topical drop, in patients with diabetic macular edema.
Latest:
Impact of Durable Therapies on Patients and Clinics and Monitoring StrategiesPanelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.
Latest:
Christina Y. Weng, MD, MBA, FASRS, on comparative study of postop day 0 and day 1 examsChristina Weng, MD, MBA, FASRS, explores the viability of postoperative day 0 exams as a substitute for day 1 after vitreoretinal surgery, revealing promising findings.
